6519 ORAL Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer
Scagliotti, G., Park, K., Patil, S., Rolski, J., Gorksel, T., Gans, S.J.M., Martins, R., Visseren-Grul, C., Peterson, P.Volume:
5
Language:
english
Journal:
European Journal of Cancer Supplements
DOI:
10.1016/S1359-6349(07)71347-2
Date:
September, 2007
File:
PDF, 57 KB
english, 2007